“Real-World” Breo Study: A Q&A With GSK’s David Leather

GlaxoSmithKline is evaluating its once-daily ICS/LABA Breo Ellipta in a “real-world” trial called the Salford Lung Study, with as little intervention from the clinical trial team as possible, to see how the product impacts health outcomes versus existing treatments. David Leather, MD, global medical affairs leader for GSK’s respiratory franchise, is heading the trial and talks about the trial design, challenges, and why the company launched the study in the first place.